MindWalk Holdings Corp. (HYFT) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, ladies and gentlemen, and thank you for joining us today for MindWalk's first quarter fiscal 2026 earnings call. We appreciate your time and interest in MindWalk, formerly Immunoprecise Antibodies. Today's call will be led by our CEO, Dr. Jennifer Bath, and interim CFO, Joe Scheffler. They will provide review of our financial performance, strategic initiatives, and key operational highlights for the first quarter. Please note that a copy of today's presentation along with our final financial statements will be available on our company's website for your reference. Before we begin, I'd like to remind everyone that today's discussion will include forward-looking statements. These are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. Factors include, but are not limited to, global political and economic conditions, changes in the market dynamics, and other business risks. Unless otherwise noted, all financial figures discussed today are in Canadian dollars and These statements are made as of today, and we undertake no obligation to update them except as required by law. For a more detailed discussion of risks and uncertainties, please refer to our filings with the SEC, including our most recent form, 20F, and other periodic reports. I would now like to turn the call over to MindWalk's President and CEO, Dr. Jennifer Bath. Thank you, Jordan, and good morning, everyone. For transparency, our first quarter results include contributions from our Netherlands operations, which we owned during the period. Six days into the second quarter, we completed the divestiture of those operations, generating $15.1 million in net proceeds. Going forward, we will classify results rel...